in vitro News and Research

RSS

Researchers develop two complementary bladder models to study UTIs

Urinary tract infections (UTIs) are among the most common bacterial infections. They usually require treatment with antibiotics, and almost a quarter of treated cases lead to recurrent infection.

30 Jul 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Oncotarget data reveals retinoic acid as fundamental regulator of cell cycle and differentiation

Oncotarget published "Role for Fgr and Numb in retinoic acid-induced differentiation and G0 arrest of non-APL AML cells" which reported that retinoic acid is a fundamental regulator of cell cycle and cell differentiation.

28 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

Budesonide’s antiviral effect against SARS-CoV-2

A new study examines the in vitro antiviral effect of pure budesonide and Pulmicort® against the SARS-CoV-2 WT and two VoCs.

26 Jul 2021

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Novel therapeutic agent could be effective for treating cancers with certain gene mutations

Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.

23 Jul 2021

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

A new study has been published on the bioRxiv* preprint server, which has used MS to identify T cell epitopes of SARS-CoV-2 conserved protein, i.e., the membrane glycol protein (MGP) and the non-structure protein-13 (NSP13).

23 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Researchers use nanoparticles as heaters to manipulate the electrical activity of neurons

Nanomaterials have been used in a variety of emerging applications, such as in targeted pharmaceuticals or to bolster other materials and products such as sensors and energy harvesting and storage devices.

22 Jul 2021

SARS-CoV-2 proteins manipulate autophagy

The ongoing coronavirus pandemic (COVID-19) has claimed more than 4.1 million lives worldwide. This pandemic is caused by a novel single-stranded RNA virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first reported in 2019 in Wuhan, China. The rapid spread of this virus is attributed to its high infectiousness and its ability to escape and counteract host immune responses, e.g., autophagy.

22 Jul 2021

Traditional Japanese dish may hold an answer to COVID-19

Natto, a fermented soybean dish often served for breakfast in Japan, originated at the turn of the last millennium but may hold an answer to a modern problem: COVID-19, according to a new study based on cell cultures.

21 Jul 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Vitamin C and TET proteins can work together to give regulatory T cells their life-saving power

You can't make a banana split without bananas. And you can't generate stable regulatory T cells without Vitamin C or enzymes called TET proteins, it appears.

21 Jul 2021

Study examines the host and viral factors that drive SARS-CoV-2 evolution

In a new paper recently uploaded to the preprint server bioRxiv*, two clinical isolates of SARS-CoV-2 are monitored by whole genome sequencing as they are passaged through several generations of Vero cells or human-derived primary nasal epithelial cells (PNEC), allowing direct observation of the occurrence of virus enhancing mutations and the way in which host cell factors shape virus evolution.

21 Jul 2021

Scientists explore susceptibility of different animals to SARS-CoV-2 infection

A team of researchers at the Institute of Infectious Diseases (IFIK) at the University of Bern and the Institute of Virology and Immunology (IVI) has utilized a unique collection of advanced cell culture models of cells lining the airways from various domesticated and wildlife animals. This way, the team can determine which animals are susceptible to SARS-CoV-2 infection.

20 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021